Stocks · Healthcare · Biotechnology
Arrowhead Pharmaceuticals, Inc. ARWR
$62.35 -2.87% Close, Oct 5, 2026 · NASDAQ · Market cap $9.04B
Strong growthHigh quality
Next earnings report: Nov 24, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -33.8% from -18.8% a year earlier.
- Over the past year the stock returned +80.2%, ahead of the S&P 500 by 64.4 percentage points.
- Revenue over the last four quarters was $669.5M, up 16.8% from a year earlier, accelerating from 14.1% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 36%
- Revenue growth, 3-year CAGRTop 14%
- Revenue growth accelerationTop 24%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 44%
- Gross marginTop 2%
- Operating marginBottom 39%
- Accruals (lower is better)Top 28%
- Interest coverBottom 48%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 40%
- Free-cash-flow yieldTop 38%
- EBITDA / enterprise valueTop 41%
- Sales / enterprise valueBottom 25%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 10%
- 6-month returnBottom 44%
- 1-year return vs S&P 500Top 20%
- Distance from 52-week highBottom 47%
- Trend checklist (0–4)Bottom 36%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 17%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 42%
- Upside to consensus price targetTop 49%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 42%
- Maximum drawdown, 3 yearsBottom 43%
- Beta vs S&P 500 (lower is better)Bottom 6%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 14.1% | 16.8% | ↑ |
| Gross margin | 99.1% | 100.0% | ↑ |
| Operating margin | -18.8% | -33.8% | ↓ |
| FCF margin | -3.1% | -11.2% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 16.8% | 14.1% | ↑ | Top 36% |
| Gross margin | 100.0% | 99.1% | ↑ | Top 2% |
| Operating margin | -33.8% | -18.8% | ↓ | Bottom 39% |
| Net margin | -47.8% | -25.9% | ↓ | — |
| Free-cash-flow margin | -11.2% | -3.1% | ↓ | — |
| Return on invested capital | -12.1% | — | Top 44% | |
| Revenue growth, 3-year CAGR | 50.5% | — | Top 14% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -12.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 10.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -28.6 pp
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -2.4×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -3.36%
- Shareholder yield
- -3.36%
- Share count change, 1 year
- +3.1%
- Share count change, 3-year CAGR
- +10.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 4, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -29.1%
- Average 2-day reaction, last 8
- +2.4%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $100.63
- Target vs current price
- +61.4%
- Analysts with a rating
- 22
- Share rating Buy or Strong Buy
- 73%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 4, 2026 | -6.3% | +4.2% | +2.7% | -4.2% | — |
| May 7, 2026 | +14.7% | -1.5% | -1.6% | -5.0% | +8.7% |
| Feb 5, 2026 | -63.3% | -5.0% | -9.6% | -6.6% | +9.9% |
| Nov 25, 2025 | -61.3% | +5.7% | +30.9% | +57.8% | +42.7% |
| Aug 7, 2025 | -34.0% | -1.5% | +22.6% | +71.7% | +159.4% |
| May 12, 2025 | +4683.3% | +7.2% | +20.6% | +27.2% | +25.2% |
| Feb 10, 2025 | -231.0% | -1.6% | -1.4% | -24.9% | -35.4% |
| Nov 26, 2024 | -31.4% | +12.0% | +38.7% | +4.5% | +3.9% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | -$1.36 | -$1.28 | -6.3% | $75.3M |
| May 7, 2026 | -$0.93 | -$1.09 | +14.7% | $73.7M |
| Feb 5, 2026 | $0.22 | $0.60 | -63.3% | $264.0M |
| Nov 25, 2025 | -$0.18 | -$0.11 | -61.3% | $256.5M |
| Aug 7, 2025 | -$1.26 | -$0.94 | -34.0% | $27.8M |
| May 12, 2025 | $2.75 | -$0.06 | +4683.3% | $542.7M |
| Feb 10, 2025 | -$1.39 | -$0.42 | -231.0% | $2.5M |
| Nov 26, 2024 | -$1.38 | -$1.05 | -31.4% | $3.6M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 14.71× | — | — | Bottom 25% |
| Free-cash-flow yield | -0.83% | — | — | Top 38% |
| Earnings yield | -3.59% | — | — | Top 40% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -4.4%
- 200-day average slope (20 days)
- +1.9%
- Distance from 50-day average
- -22.4%
- Distance from 200-day average
- -14.0%
- RSI (14)
- 27.8
- Relative volume
- 0.96×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 59.8%
- Volatility vs own 5-year history
- 44th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.48
- Correlation with S&P 500
- 0.53
- Current drawdown from 1-year high
- -30.4%
- Maximum drawdown, 3 years
- -74.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 5, 2021 | Apr 8, 2025 | -89.0% | 1047 days | Not yet recovered |
| Nov 17, 2020 | Nov 25, 2020 | -19.4% | 6 days | 10 days (Dec 10, 2020) |
| Dec 23, 2020 | Jan 5, 2021 | -14.9% | 7 days | 22 days (Feb 5, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $9.04B
- EPS, diluted (TTM)
- -$2.24
- Revenue (TTM)
- $669.5M
- 52-week range
- $34.61 – $95.49
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $138.3M | $243.2M | $240.7M | $3.6M | $829.4M |
| Gross profit | $138.3M | $232.8M | $228.2M | -$15.0M | $829.4M |
| Operating income | -$149.0M | -$178.5M | -$205.0M | -$601.1M | $98.3M |
| Net income | -$140.8M | -$176.1M | -$205.3M | -$599.5M | -$1.6M |
| EPS (diluted) | -$1.36 | -$1.67 | -$1.92 | -$5.00 | -$0.01 |
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $2.5M | $542.7M | $27.8M | $256.5M | $264.0M | $73.7M | $75.3M |
| Net income | -$170.5M | -$173.1M | $370.4M | -$175.2M | -$23.8M | $30.8M | -$132.7M | -$194.3M |
| EPS (diluted) | -$1.40 | -$1.39 | $2.75 | -$1.26 | -$0.17 | $0.22 | -$0.93 | -$1.36 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $171.3M | -$136.1M | -$153.9M | -$462.9M | $179.6M |
| Capital expenditure | -$23.6M | -$52.8M | -$176.7M | -$141.5M | -$22.7M |
| Free cash flow | $147.7M | -$188.9M | -$330.6M | -$604.3M | $156.9M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $0 | $5.2M | $3.1M | $431.7M | $270.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $1.60B
- Total assets
- $2.11B
- Total liabilities
- $1.65B
- Total debt
- $864.1M
- Net debt
- $809.3M
- Shareholders’ equity
- $465.5M
As of Jun 30, 2026 (filed Aug 4, 2026).
Short interest
- Shares sold short
- 9,272,290
- Days to cover
- 5.15
- Change vs previous report
- -1.6%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Nov 17, 2011
- 1-for-10
- Jan 15, 2004
- 1-for-65